JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2005; 46:1855-1862, doi:10.1016/j.jacc.2005.05.085 (Published online 20 October 2005).
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2005.05.085v1
46/10/1855    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (49)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robinson, J. G.
Right arrow Articles by Schrott, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robinson, J. G.
Right arrow Articles by Schrott, H.

CLINICAL RESEARCH: ATHEROSCLEROSIS

Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?

A Meta-Regression Analysis

Jennifer G. Robinson, MD, MPH*,*, Brian Smith, MS, PhD{dagger}, Nidhi Maheshwari, MBBS* and Helmut Schrott, MD*

* Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa
{dagger} Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa

Manuscript received March 9, 2005; revised manuscript received April 25, 2005, accepted May 15, 2005.

* Reprint requests and correspondence: Dr. Jennifer G. Robinson, 200 Hawkins Drive, SE226GH, Iowa City, Iowa 52242. (Email: jennifer-g-robinson{at}uiowa.edu).

OBJECTIVES: This study sought to determine whether statins reduce coronary heart disease (CHD) risk more than other interventions that also primarily lower low-density lipoprotein cholesterol (LDL-C).

BACKGROUND: Statins have anti-inflammatory, immunomodulatory, antithrombotic, vascular, and other non–LDL-C-lowering effects. It is unclear whether these pleiotropic effects contribute to cardiovascular risk reduction beyond that expected from LDL-C reduction alone.

METHODS: Trials published in English language journals were retrieved by searching Medline (1966 to October 2004), bibliographies, and the author’s reference files. Randomized, placebo-controlled trials of interventions to primarily lower LDL-C of three or more years’ duration in which clinical disease or death were primary outcomes were used. Information on sample size, treatment type and duration, participant characteristics at baseline, reduction in lipids, and outcome was independently abstracted by two authors (J.R. and N.M.) using a standardized protocol. Data from 5 diet, 3 bile acid sequestrant, 1 surgery, and 10 statin trials, with 81,859 participants, were included in the CHD meta-regression analysis.

RESULTS: The regression lines for non-statin and statin trials were similar and consistent with a one-to-one relationship between LDL-C lowering and CHD and stroke reduction over five years of treatment.

CONCLUSIONS: The pleiotropic effects of statins do not seem to contribute an additional cardiovascular risk reduction benefit beyond that expected from the degree of LDL-C lowering observed in other trials that primarily lowered LDL-C.

Abbreviations and Acronyms
  CHD = coronary heart disease
  LDL-C = low-density lipoprotein cholesterol
  MI = myocardial infarction
  PROSPER = PROspective Study of Pravastatin in the Elderly at Risk
  PROVE-IT = Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction-22
  TNT = Treating to New Targets




This article has been cited by other articles:


Home page
 Eur Heart JHome page
M. Settergren, F. Bohm, L. Ryden, and J. Pernow
Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease
Eur. Heart J., July 2, 2008; 29(14): 1753 - 1760.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S. Kinlay
Vascular form and function: two mechanisms for cardiovascular prevention
Eur. Heart J., July 2, 2008; 29(14): 1711 - 1713.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
F. S. Resnic and A. Desai
Highlights from the 57th Annual Scientific Session of the American College of Cardiology
J. Thorac. Cardiovasc. Surg., July 1, 2008; 136(1): 244 - 247.
[Full Text] [PDF]

Home page
 NEJMHome page
J. J.P. Kastelein, F. Akdim, E. S.G. Stroes, A. H. Zwinderman, M. L. Bots, A. F.H. Stalenhoef, F. L.J. Visseren, E. J.G. Sijbrands, M. D. Trip, E. A. Stein, et al.
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
N. Engl. J. Med., April 3, 2008; 358(14): 1431 - 1443.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
G. F M Strippoli, S. D Navaneethan, D. W Johnson, V. Perkovic, F. Pellegrini, A. Nicolucci, and J. C Craig
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials
BMJ, March 22, 2008; 336(7645): 645 - 651.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
K. Josan MD, S. R. Majumdar MD MPH, and F. A. McAlister MD MSc
The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials
Can. Med. Assoc. J., February 26, 2008; 178(5): 576 - 584.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. O. Mudd, B. A. Borlaug, P. V. Johnston, B. G. Kral, R. Rouf, R. S. Blumenthal, and P. O. Kwiterovich Jr
Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease
J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1735 - 1741.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. C. LaRosa
Means and Ends of Statins and Low-Density Lipoprotein Cholesterol Lowering
J. Am. Coll. Cardiol., July 31, 2007; 50(5): 419 - 420.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. A. Alsheikh-Ali, P. V. Maddukuri, H. Han, and R. H. Karas
Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
J. Am. Coll. Cardiol., July 31, 2007; 50(5): 409 - 418.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
S. Mangat, S. Agarwal, and C. Rosendorff
Do Statins Lower Blood Pressure?
Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 112 - 123.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
E. M. Tuzcu and S. J. Nicholls
Statins: Targeting Inflammation by Lowering Low-Density Lipoprotein?
J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2010 - 2012.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Kinlay
Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein: A Meta-Analysis
J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2003 - 2009.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
T. N. Patel, M. H. Shishehbor, and D. L. Bhatt
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Eur. Heart J., March 2, 2007; 28(6): 664 - 672.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
J. G. Robinson, G. Bakris, J. Torner, N. J. Stone, and R. Wallace
Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?
Stroke, February 1, 2007; 38(2): 441 - 450.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
I. Karp, S.-F. Chen, and L. Pilote
Sex differences in the effectiveness of statins after myocardial infarction
Can. Med. Assoc. J., January 30, 2007; 176(3): 333 - 338.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. Napoli, L. O. Lerman, F. de Nigris, M. Gossl, M. L. Balestrieri, and A. Lerman
Rethinking Primary Prevention of Atherosclerosis-Related Diseases
Circulation, December 5, 2006; 114(23): 2517 - 2527.
[Full Text] [PDF]

Home page
 Am J Crit CareHome page
K. B. Keller and L. Lemberg
Secondary prevention of coronary artery disease in elderly persons: a treatise on a report by the american heart association.
Am. J. Crit. Care., September 1, 2006; 15(5): 514 - 518.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. Poli and A. Pujia
Pleiotropic Effects of Statins and Early Benefit in the PROVE IT-TIMI-22 Study
J. Am. Coll. Cardiol., August 15, 2006; 48(4): 852 - 852.
[Full Text] [PDF]

Home page
 JAMAHome page
H. K. Berthold, S. Unverdorben, R. Degenhardt, M. Bulitta, and I. Gouni-Berthold
Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.
JAMA, May 17, 2006; 295(19): 2262 - 2269.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
B. M. Scirica, D. A. Morrow, S. Verma, S. Devaraj, I. Jialal, B. M. Scirica, D. A. Morrow, S. Verma, S. Devaraj, and I. Jialal
The Verdict Is Still Out
Circulation, May 2, 2006; 113(17): 2128 - 2151.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. C. LaRosa
At the Heart of the Statin Benefit
J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1863 - 1863.
[Full Text] [PDF]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2005 by the American College of Cardiology Foundation.